Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Research and Innovation Action · Running

RadioVal International Clinical Validation of Radiomics Artificial Intelligence for Breast Cancer Treatment Planning

Coordinator
Universitat De Barcelona, Spain
Runs
1 September 2022 to 28 February 2027
Status
Running
EU funding
€5.8m
Total cost
€5.8m
Partners
16 organisations in 13 countries
Type
Research and Innovation Action
Grant agreement
101057699

What the project is doing

In the project's own words, from its summary on CORDIS.

Breast cancer is now the most common cancer worldwide, surpassing lung cancer in 2020 for the first time. It is responsible for almost 30% of all cancers in women and current trends show its increasing incidence. Neoadjuvant chemotherapy (NAC) has shown promise in reducing mortality for advanced cases, but the therapy is associated with a high rate of over-treatment, as well as with significant side effects for the patients.

For predicting NAC respondents and improving patient selection, artificial intelligence (AI) approaches based on radiomics have shown promising preclinical evidence, but existing studies have mostly focused on evaluating model accuracy, all-too-often in homogeneous populations. RadioVal is the first multi-centre, multi-continental and multi-faceted clinical validation of radiomics-driven estimation of NAC response in breast cancer.

The project builds on the repositories, tools and results of five EU-funded projects from the AI for Health Imaging (AI4HI) Network, including a large multi-centre cancer imaging dataset on NAC treatment in breast cancer. To test applicability as well as transferability, the validation with take place in eight clinical centres from three high-income EU countries (Sweden, Austria, Spain), two emerging EU countries (Poland, Croatia), and three countries from South America (Argentina), North Africa (Egypt) and Eurasia (Turkey).

RadioVal will develop a comprehensive and standardised methodological framework for multi-faceted radiomics evaluation based on the FUTURE-AI Guidelines, to assess Fairness, Universality, Traceability, Usability, Robustness and Explainability. Furthermore, the project will introduce new tools to enable transparent and continuous evaluation and monitoring of the radiomics tools over time. The RadioVal study will be implemented through a multi-stakeholder approach, taking into account clinical and healthcare needs, as well as socio-ethical and regulatory requirements from day one.

Topics

Who is involved

OrganisationCityCountryRole
Universitat De BarcelonaBarcelonaSpainCoordinator
Alexander Fleming SABuenos AiresARParticipant
Eibir Gemeinnutzige GmbH Zur Forderung Der Erforschung Der Biomedizinischen BildgebungWienAustriaParticipant
Medizinische Universitaet WienWienAustriaParticipant
Ain Shams UniversityAbassyia CairoEgyptParticipant
Idryma Technologias Kai ErevnasIrakleioGreeceParticipant
Fundacion Para La Investigacion Del Hospital Universitario La Fe De La Comunidad ValencianaValenciaSpainParticipant
Quibim Sociedad LimitadaValenciaSpainParticipant
Nhg Finland OyHelsinkiFinlandParticipant
Sveuciliste U Zagrebu Medicinski FakultetZagrebCroatiaParticipant
Maggioli S.p.a.Santarcangelo Di RomagnaItalyParticipant
Universiteit MaastrichtMaastrichtNetherlandsParticipant
Gdanski Uniwersytet MedycznyGdanskPolandParticipant
Shine 2europe LdaCoimbraPortugalParticipant
Karolinska InstitutetStockholmSwedenParticipant
Hacettepe UniversitesiCankaya AnkaraTürkiyeParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI